Alpha Oncology Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$87,536	4
2024	Research	$42,931	3
2023	Research	$98,992	6
2022	Research	$38,316	2
2020	Research	$9,761	2

Breakdown

Who paid Research payments · program years 2020–2025

Novartis Pharmaceuticals Corporation $230,626 10 payments
MorphoSys AG $37,149 5 payments
United Therapeutics Corporation $9,761 2 payments

Studies the money was for Research payments · program years 2020–2025

A Phase II Multicenter Study to Confirm PK PD of Crizanlizumab With Or Without Hydroxyurea Hydroxycarbamide in Adult Sickle Cell Disease Patients With History of Voc $98,457 2 payments
A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer $42,925 2 payments
KontRASt-08: A randomized, multicenter phase II/III study evaluating the efficacy and safety of opnurasib (JDQ443) combined with pembrolizumab versus pembrolizumab as first-line therapy for adult participants with locally advanced or metastatic non-squamo $42,120 1 payment
A randomized, multicenter phase II/III study evaluating the efficacy and safety of opnurasib (JDQ443) combined with pembrolizumab plus platinum and pemetrexed versus pembrolizumab plus platinum and pemetrexed as first-line therapy for adult participants w $28,020 1 payment
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind $20,538 1 payment
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) $16,611 4 payments
A randomized, multicenter phase II/III study evaluating the efficacy and safety of opnurasib (JDQ443) combined with pembrolizumab plus platinum and pemetrexed versus pembrolizumab plus platinum and pemetrexed as first-line therapy for adult participants with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring KRAS G12C mutation and PD-L1 expression <50% $14,939 1 payment
A Two-Part Open-Label Randomized Phase II/III Study of Dinutuximab and Irinotecan Versus Irinotecan for Second-Line Treatment of Subjects With Relapsed Or Refractory Small Cell Lung Cancer $9,761 2 payments
A Post-Trial Access Roll-Over Study to Allow Access to Ribociclib (Lee011) for Patients Who Are on Ribociclib Treatment in Novartis-Sponsored Study $4,165 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.